Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
4.110
-0.030 (-0.72%)
At close: Jun 23, 2026, 4:00 PM EDT
4.098
-0.012 (-0.28%)
After-hours: Jun 23, 2026, 7:59 PM EDT
Elicio Therapeutics Employees
Elicio Therapeutics had 33 employees as of December 31, 2025. The number of employees increased by 1 or 3.13% compared to the previous year.
Employees
33
Change (1Y)
1
Growth (1Y)
3.13%
Revenue / Employee
n/a
Profits / Employee
-$1,217,727
Market Cap
75.61M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 33 | 1 | 3.13% |
| Dec 31, 2024 | 32 | 0 | - |
| Dec 31, 2023 | 32 | 9 | 39.13% |
| Dec 31, 2022 | 23 | -1 | -4.17% |
| Dec 31, 2021 | 24 | 2 | 9.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MindWalk Holdings | 102 |
| XBiotech | 87 |
| Acrivon Therapeutics | 76 |
| Pliant Therapeutics | 49 |
| BeyondSpring | 44 |
| eXoZymes | 32 |
| ImageneBio | 17 |
| Edesa Biotech | 17 |
ELTX News
- 5 days ago - Elicio Therapeutics assumed with a Buy at Ladenburg - TheFly
- 6 days ago - Elicio Therapeutics reports complete responses in pancreatic cancer trial - TheFly
- 6 days ago - Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer - GlobeNewsWire
- 7 days ago - Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) - PRNewsWire
- 8 days ago - Elicio Therapeutics downgraded to Hold from Buy at JonesResearch - TheFly
- 8 days ago - Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal - Reuters
- 8 days ago - Elicio selloff brings attractive entry point, says H.C. Wainwright - TheFly
- 8 days ago - Elicio Therapeutics Transcript: Study update - Transcripts